local_hospital

Institutul Național de Gerontologie și Geriatrie​ "Ana Aslan"

Address
lock Available on a paid plan

Psychiatry and Psychology at Institutul Național de Gerontologie și Geriatrie “Ana Aslan”

This site is conducting clinical research in mental disorders, with studies focused on bipolar-I disorder and mania. The work is aimed at understanding how new treatments may help manage mood symptoms more effectively and support longer-term care.

  • Evaluating a new therapy for manic episodes in bipolar-I disorder
  • Assessing the long-term safety and tolerability of treatment for mania with mixed features

The research at this Bucharest site reflects a strong interest in improving treatment options for serious psychiatric conditions that can affect daily functioning and quality of life.

Neurocognitive Disorders and Brain Health

Another major area of study at the site involves Alzheimer’s disease, especially mild to moderate Alzheimer’s disease with cognitive impairment and reduced global functioning. These trials are designed to explore whether new treatment approaches can help preserve thinking skills and overall independence.

  • Testing a potential therapy for Alzheimer’s disease and related cognitive symptoms
  • Measuring whether treatment can improve thinking skills and global functioning

This research supports efforts to better understand and treat memory and reasoning problems in older adults, aligning with the geriatric expertise of the Institutul Național de Gerontologie și Geriatrie “Ana Aslan”.

Site Overview

assignment
3
connected trials
corporate_fare
1
sponsor
science
2
IMPs

Activity Indicator

Last 6 months

0
Trials started
-100% vs previous period.
2
Trials started 6–12 months ago
3
Total trials linked
Moderately Active
trending_downDeclining-100%
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status
lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years
lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
3
Sponsors (total)
1
Active sponsors
1

Sponsor Network

Top 1 by active trials.

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 442 other sites in Romania

description
Trial volume
3
Outperforms 50% of sites
public
Therapeutic diversity
1areas
Outperforms 2% of sites
groups
Sponsor diversity
1sponsors
Outperforms 2% of sites

Therapeutic Area Benchmark — Romania

Select a therapeutic area to compare against other sites in Romania.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Romania

Market Share

Country: Romania

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Institutul Național de Gerontologie și Geriatrie​ "Ana Aslan"

lock Showing 1 of 3 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated with Mild to Moderate Alzheimer’s Disease (MINDSET 1)Bristol-Myers Squibb Services Unlimited CompanyPhase IIIRecruitingNov 2025

IMP list

lock Showing 1 of 2 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Trospium Chloride3Unknown2025-09-252026-03-02

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.